Source:http://linkedlifedata.com/resource/pubmed/id/17762400
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2007-8-31
|
| pubmed:abstractText |
This study assessed the clinical activity and safety of twice-weekly paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin (TP-HDFL) in patients with recurrent or metastatic esophageal squamous cell carcinoma. The regimen, composed of paclitaxel 35 mg/m 1-h intravenous infusion on days 1, 4, 8 and 11; cisplatin 20 mg/m 2-h intravenous infusion on days 2, 5, 9 and 12; and 5-flourouracil 2000 mg/m and leucovorin 300 mg/m 24-h intravenous infusion on days 5 and 12; repeated every 21 days. Forty-one patients (median age 51), 15 with de-novo metastatic disease and 26 with recurrent disease, were enrolled. Grades 3-4 neutropenia, leukopenia and diarrhea occurred in 37.8, 29.4 and 14.2% of cycles, respectively. One patient died of invasive fungal infection. Three complete responses, 13 partial response and 13 stable diseases were observed. The intent-to-treat response rate was 39.0% (95% confidence interval: 24-54). The median progression-free and overall survival were 6.3 and 8.9 months (range 1-50+), respectively. Twice-weekly TP-HDFL has the activity and toxicity profile similar to the previously reported same three-drug combination for advanced esophageal cancer.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
0959-4973
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
18
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
703-8
|
| pubmed:meshHeading |
pubmed-meshheading:17762400-Adult,
pubmed-meshheading:17762400-Aged,
pubmed-meshheading:17762400-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17762400-Carcinoma, Squamous Cell,
pubmed-meshheading:17762400-Cisplatin,
pubmed-meshheading:17762400-Disease-Free Survival,
pubmed-meshheading:17762400-Drug Administration Schedule,
pubmed-meshheading:17762400-Esophageal Neoplasms,
pubmed-meshheading:17762400-Female,
pubmed-meshheading:17762400-Fluorouracil,
pubmed-meshheading:17762400-Humans,
pubmed-meshheading:17762400-Infusions, Intravenous,
pubmed-meshheading:17762400-Leucovorin,
pubmed-meshheading:17762400-Male,
pubmed-meshheading:17762400-Middle Aged,
pubmed-meshheading:17762400-Neoplasm Metastasis,
pubmed-meshheading:17762400-Neoplasm Recurrence, Local,
pubmed-meshheading:17762400-Paclitaxel
|
| pubmed:year |
2007
|
| pubmed:articleTitle |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma.
|
| pubmed:affiliation |
Department of Oncology, National Taiwan University, Taipei, Taiwan, ROC.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II
|